BrainStorm Cell Therapeutics, a biotechnology company focused on developing stem cell therapies for neurodegenerative diseases, has completed treatment of all patients enrolled in its Phase II clinical trial of NurOwn in the US. NurOwn is an adult stem cell therapy that uses bone marrow-derived autologous mesenchymal stem cells (MSC), which secrete neurotrophic factors. The MSCs are administered into patients via intramuscular and intrathecal injections. The Phase II trial, which followed after a Phase IIa clinical trial in Israel (see Jan 2015 news), was a double-blind study of safety and efficacy of NurOwn treatment as compared to placebo in ALS patients.
Click here to read more.